Yu H, Diamandis E P, Levesque M, Sismondi P, Zola P, Katsaros D
Department of Clinical Biochemistry, Toronto Hospital, Ontario, Canada.
J Clin Lab Anal. 1994;8(4):251-3. doi: 10.1002/jcla.1860080412.
We have recently reported that about 30% of breast tumors produce prostate specific antigen (PSA). We examined here, 99 primary ovarian cancer tumors and found relatively low levels of PSA in only three tumors. One patient with metastatic ovarian cancer from a primary breast tumor, produced relatively high levels of PSA and responded well to antiestrogen treatment although she was steroid receptor-negative. Another patient with metastatic ovarian cancer from a primary breast tumor did not produce PSA and did not respond to treatment although she was steroid hormone receptor-positive. This data describe for the first time, ectopic PSA production by a breast tumor at the ovarian metastatic site and further support the view that PSA is a favourable prognostic indicator in breast cancer.
我们最近报道，约30%的乳腺肿瘤会产生前列腺特异性抗原（PSA）。我们在此检测了99例原发性卵巢癌肿瘤，仅在3例肿瘤中发现PSA水平相对较低。一名来自原发性乳腺肿瘤的转移性卵巢癌患者，PSA水平相对较高，且对抗雌激素治疗反应良好，尽管她的类固醇受体呈阴性。另一名来自原发性乳腺肿瘤的转移性卵巢癌患者不产生PSA，对治疗无反应，尽管她的类固醇激素受体呈阳性。这些数据首次描述了乳腺肿瘤在卵巢转移部位产生异位PSA的情况，并进一步支持了PSA是乳腺癌良好预后指标的观点。
